MyoKardia, Inc. Common Stock
MYOK
MYOK was delisted on the 16th of November, 2020.
157 hedge funds and large institutions have $2.55B invested in MyoKardia, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 56 increasing their positions, 48 reducing their positions, and 23 closing their positions.
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
17% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 48
13% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 23
7% more capital invested
Capital invested by funds: $2.39B → $2.55B (+$160M)
1% more funds holding
Funds holding: 155 → 157 (+2)
19% less call options, than puts
Call options by funds: $4.77M | Put options by funds: $5.89M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$26.6M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$17.2M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
+$15.2M |
| 4 |
BlackRock
New York
|
+$14.6M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$9.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$29.2M |
| 2 |
Millennium Management
New York
|
-$13.1M |
| 3 |
O
OrbiMed
New York
|
-$9.16M |
| 4 |
CC
Casdin Capital
New York
|
-$9.04M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$7.02M |
MYOK Hedge Fund Activity: Q3 2019 in Review
157 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in MyoKardia, Inc. Common Stock (MYOK) for Q3 2019, worth a combined $2.55B — up 6.7% from $2.39B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new MYOK positions and 23 closed out — a net gain of 3 holders — while 56 added to existing stakes and 48 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $26.6M. The largest seller was PFM Health Sciences, cutting an estimated $29.2M.
- 157 institutional investors held MyoKardia, Inc. Common Stock (MYOK) as of Q3 2019, up from 155 in Q2 2019.
- Funds reported $2.55B of MyoKardia, Inc. Common Stock stock for Q3 2019, up 6.7% quarter-over-quarter.
- 26 funds opened new MyoKardia, Inc. Common Stock positions in Q3 2019 and 23 closed out, a net change of +3 holders.
- The largest MyoKardia, Inc. Common Stock buyer in Q3 2019 was Baker Bros. Advisors, an estimated $26.6M added.
- The largest MyoKardia, Inc. Common Stock seller in Q3 2019 was PFM Health Sciences, an estimated $29.2M sold.
Based on aggregated 13F filings for Q3 2019.